Evidence map›Paper›PMID 35631358›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Covalent Inhibition of the

Natalia Serrano-Aparicio, Silvia Ferrer, Katarzyna Świderek

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. The pivotal role of β-lactone stereochemistry in the development of SARS-CoV-2 MProtein science : a publication of the Protein Society · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Natalia Serrano-AparicioBioComp Group, Department of Physical and Analytical Chemistry, Universitat Jaume I, 12071 Castellón de la Plana, Spain.
Silvia FerrerBioComp Group, Department of Physical and Analytical Chemistry, Universitat Jaume I, 12071 Castellón de la Plana, Spain.
Katarzyna ŚwiderekBioComp Group, Department of Physical and Analytical Chemistry, Universitat Jaume I, 12071 Castellón de la Plana, Spain.ORCID 0000-0002-7528-1551
Universitat Jaume I · ES

Funding

GVA, Subvenciones Excelencia Científica Juniors Investigadores, SEJI SEJI/2020/007Ministerio de Ciencia e Innovación, Spain RYC2020-030596-IMinisterio de Ciencia, Innovación y Universidades PID2019-107098RJ-I00Universitat Jaume I UJI-A2019-04
6 · The paper itself

Abstract

20S proteasome is a main player in the protein degradation pathway in the cytosol, thus intervening in multiple pivotal cellular processes. Over the years the proteasome has emerged as a crucial target for the treatment of many diseases such as neurodegenerative diseases, cancer, autoimmune diseases, developmental disorders, cystic fibrosis, diabetes, cardiac diseases, atherosclerosis, and aging. In this work, the mechanism of proteasome covalent inhibition with bisbenzyl-protected homobelactosin C (hBelC) was explored using quantum mechanics/molecular mechanics (QM/MM) methods. Molecular dynamic simulations were used to describe key interactions established between the hBelC and its unique binding mode in the primed site of the β5 subunit. The free energy surfaces were computed to characterize the kinetics and thermodynamics of the inhibition process. This study revealed that although the final inhibition product for hBelC is formed according to the same molecular mechanism as one described for hSalA, the free energy profile of the reaction pathway differs significantly from the one previously reported for γ-lactam-β-lactone containing inhibitors in terms of the height of the activation barrier as well as the stabilization of the final product. Moreover, it was proved that high stabilization of the covalent adduct formed between β5-subunit and hBelC, together with the presence of aminocarbonyl side chain in the structure of the inhibitor which prevents the hydrolysis of the ester bond from taking place, determines its irreversible character.

Indexed as

20S proteasomecovalent inhibitionfree energyhomobelactosin CM06-2Xmolecular dynamicmolecular mechanismQM/MMumbrella samplingβ-lactone

Identifiers

PMID35631358
PMCPMC9143130
OpenAlexW4224928719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.